#AAN2018: Biogen’s BIIB054 Shows Positive Data in Phase 1 Parkinson’s Trial
Parkinson’s treatment candidate BIIB054 was well-tolerated and had a favorable pharmacological profile in preliminary Phase 1 clinical results. Biogen will…
Articles by José Lopes, PhD
#AAN2018- Inbrija Reduces Parkinson’s Off Periods, Phase 3 Trial Shows
Inbrija reduces Parkinson’s symptoms when standard treatments wear off, and decreases the length of these off periods, a Phase 3…
Survey Shows Canadian Parkinson’s Community’s Key Concerns
Long waits for diagnosis, limited access to specialized treatments and services, and out-of-pocket healthcare costs are among key concerns of…
Michael J. Fox Foundation Offers Educational Tool to Boost Participation in Parkinson’s Clinical Studies
The Michael J. Fox Foundation for Parkinson’s Research (MJFF) has launched an educational suite called “Parkinson’s Clinical Trial…
New Montreal Scale Is Reliable Predictor of Parkinson’s Dementia, Study Finds
Montreal researchers have developed a scale that doctors can use in their office to predict Parkinson’s patients’ risk of developing…
Brain Training, Medication Could Reduce Parkinson’s Patients’ Falls, Study Reports
Brain training can improve the mobility and reduce the risk of falls among older people with dementia and cognitive impairment,…
Sunovion Seeks FDA Approval of Below-the-Tongue Apomorphine for Parkinson’s Off Periods
Sunovion Pharmaceuticals has asked the U.S. Food and Drug Administration to begin a regulatory review of its below-the-tongue formulation of…
Limited Increase in Heart Rate as Blood Pressure Falls Could Indicate Parkinson’s, Study Reports
A simple bedside test measuring heart rate and blood pressure after a patient stands may help doctors come up with…
New AI Model May Improve Use of Touchscreens by Patients with Parkinson’s, Other Disabilities
Finnish and Japanese researchers have developed a new algorithmic approach to user interface optimization that takes individual differences into account. This approach…
Acorda Asks European Union to Approve Inbrija for Parkinson’s Off Periods
Acorda Therapeutics has asked the European Medicines Agency to approve Inbrija (CVT-301) to reduce the periods when the standard …